Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer

被引:351
作者
Zhang, Shiyu [1 ]
Royer, Robert [1 ]
Li, Song [1 ]
McLaughlin, John R. [2 ]
Rosen, Barry [3 ]
Risch, Harvey A. [4 ]
Fan, Isabel [2 ]
Bradley, Linda [2 ]
Shaw, Patricia A. [5 ]
Narod, Steven A. [1 ]
机构
[1] Univ Toronto, Womens Coll Res Inst, Toronto, ON M5G 1N8, Canada
[2] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada
[3] Univ Toronto, Dept Gynecol, Princess Margaret Hosp, Toronto, ON M5G 1N8, Canada
[4] Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06510 USA
[5] Univ Toronto, Princess Margaret Hosp, Dept Pathol, Toronto, ON M5G 1N8, Canada
基金
加拿大健康研究院;
关键词
Ovarian cancer; BRCA1; BRCA2; LARGE GENOMIC DELETIONS; ORAL-CONTRACEPTIVES; BREAST; WOMEN; RISK; FAMILIES; FEATURES; ONTARIO; GENE;
D O I
10.1016/j.ygyno.2011.01.020
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Background. The heritable fraction of ovarian cancer exceeds that of any other common adult cancer. Most inherited cases of ovarian cancer are due to a germline mutation in BRCA1 or BRCA2. It is important to have an accurate estimate of the proportion of ovarian cancer patients who carry a mutation and the specific factors which predict the presence of a mutation. Methods. We tested a population-based series of 1342 unselected patients diagnosed with invasive ovarian cancer between 1995-1999 and 2002-2004 in Ontario, Canada, for germline mutations in BRCA1 and BRCA2. The two genes were tested in their entirety, using a range of techniques, including multiplex ligation-dependent probe amplification (MLPA). Results. Among the 1342 women, 176 women carried a mutation (107 in BRCA1, 67 in BRCA2, and two in both genes) for a combined mutation frequency of 13.3%. Seven deletions were identified using MLPA (3.9% of all detected mutations). The prevalence of mutations was particularly high among women diagnosed in their forties (24.0%), in women with serous ovarian cancer (18.0%) and women of Italian (43.5%), Jewish (30.0%) or Indo-Pakistani origin (29.4%). A mutation was seen in 33.9% of women with a first-degree relative with breast or ovarian cancer and in 7.9% of women with no first-degree relative with breast or ovarian cancer. No mutation was seen in women with mucinous carcinoma. Conclusions. BRCA1 and BRCA2 mutations are common in women with invasive ovarian cancer. All women diagnosed with invasive non-mucinous ovarian cancer should be considered to be candidates for genetic testing. (C) 2011 Elsevier Inc. All rights reserved.
引用
收藏
页码:353 / 357
页数:5
相关论文
共 25 条
[1]
Large genomic deletions inactivate the BRCA2 gene in breast cancer families [J].
Agata, S ;
Dalla Palma, M ;
Callegaro, M ;
Scaini, MC ;
Menin, C ;
Ghiotto, C ;
Nicoletto, O ;
Zavagno, G ;
Chieco-Bianchi, L ;
D'Andrea, E ;
Montagna, M .
JOURNAL OF MEDICAL GENETICS, 2005, 42 (10) :e64
[2]
[Anonymous], Breast Cancer Information Core
[3]
Clinicopathologic features of BRCA-linked and sporadic ovarian cancer [J].
Boyd, J ;
Sonoda, Y ;
Federici, MG ;
Bogomolniy, F ;
Rhei, E ;
Maresco, DL ;
Saigo, PE ;
Almadrones, LA ;
Barakat, RR ;
Brown, CL ;
Chi, DS ;
Curtin, JP ;
Poynor, EA ;
Hoskins, WJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (17) :2260-2265
[4]
Improved survival in women with BRCA-associated ovarian carcinoma [J].
Cass, I ;
Baldwin, RL ;
Varkey, T ;
Moslehi, R ;
Narod, SA ;
Karlan, BY .
CANCER, 2003, 97 (09) :2187-2195
[5]
Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation [J].
Finch, Amy ;
Beiner, Mario ;
Lubinski, Jan ;
Lynch, Henry T. ;
Moller, Pal ;
Rosen, Barry ;
Murphy, Joan ;
Ghadirian, Parviz ;
Friedman, Eitan ;
Foulkes, William D. ;
Kim-Sing, Charmaine ;
Wagner, Teresa ;
Tung, Nadine ;
Couch, Fergus ;
Stoppa-Lyonnet, Dominique ;
Ainsworth, Peter ;
Daly, Mary ;
Pasini, Babara ;
Gershoni-Baruch, Ruth ;
Eng, Charis ;
Olopade, Olufunmilayo I. ;
McLennan, Jane ;
Karlan, Beth ;
Weitzel, Jeffrey ;
Sun, Ping ;
Narod, Steven A. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (02) :185-192
[6]
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers. [J].
Fong, Peter C. ;
Boss, David S. ;
Yap, Timothy A. ;
Tutt, Andrew ;
Wu, Peijun ;
Mergui-Roelvink, Marja ;
Mortimer, Peter ;
Swaisland, Helen ;
Lau, Alan ;
O'Connor, Mark J. ;
Ashworth, Alan ;
Carmichael, James ;
Kaye, Stan B. ;
Schellens, Jan H. M. ;
de Bono, Johann S. .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (02) :123-134
[7]
Gross E, 2000, HUM MUTAT, V16, P345, DOI 10.1002/1098-1004(200010)16:4<345::AID-HUMU7>3.0.CO
[8]
2-#
[9]
Hogervorst FBL, 2003, CANCER RES, V63, P1449
[10]
The BRCA1 exon 13 duplication in the Swedish population [J].
Kremeyer, B ;
Soller, M ;
Lagerstedt, K ;
Maguire, P ;
Mazoyer, S ;
Nordling, M ;
Wahlström, J ;
Lindblom, A .
FAMILIAL CANCER, 2005, 4 (02) :191-194